Abstract

Mechanism of forming new capillary from basal vessels, named angiogenesis, exist under both physiological and pathological conditions. Initiation of this process requires imbalance between proangiogenic and antiangiogenic factors, which can occur for instance under hypoxic conditions. Angiogenesis is complex process which allow tumor cells to proliferate, thus providing tumor to increase its structure. This dependence is highly connected to enhanced migration of tumor cells through blood, which often ends up being an onset of metastasis. It has been proved that capillaries that form during tumor lifetime are different in case of morphology. However, it seems that antigens spread through these blood vessel are the same as antigens produced during physiological angiogenesis. In recent years angiogenesis has become one of the most important targets in therapies used in oncology. Antiangiogenic therapies have proven itself to be very spectacular and promising in treatment of renal and pancreatic cancers or multiple myeloma. Bewacizumab, Sunitinib, Cetuximab and Talidomid are examples of drugs used in such therapies. Tyrosine kinase inhibitors are group that represents most of the drugs of antiangiogenic properties. It is worth mentioning that during administration of such substances spectrum of side effects is observed. However, antiangiogenic therapy is one of the most promising targets in today’s oncology. Therefore, it is highly explainable to continue further research in this area.

References

• 1. Ahluwalia A., Tarnawski A.S.: Critical role of hypoxia sensor – HIF-1α in VEGF gene activation. Implications for angiogenesis and tissueinjury healing. Curr. Med. Chem., 2012; 19: 90-97
  Google Scholar
• 2. Akslen L.A., Straume O., Geisler S., Sorlie T., Chi J.T., Aas T., Borresen-DaleA.L., Lonning P.E.: Glomeruloid microvascular proliferationis associated with lack of response to chemotherapy in breastcancer. Br. J. Cancer., 2011; 105: 9-12
  Google Scholar
• 3. Alfaidy N., Hoffmann P., Boufettal H., Samouh N., AboussaouiraT., Benharouga M., Feige J.J., Brouillet S.: The multiple roles of EGVEGF/PROK1in normal and pathological placental angiogenesis.Biomed. Res. Int., 2014; 2014: 451906
  Google Scholar
• 4. Antoniak K., Nowak J.Z.: Bewacizumab – postęp w leczeniu nowotworówz przerzutami i nadzieja pacjentów z retinopatią proliferacyjną.Postępy Hig. Med. Dośw., 2007; 61: 320-330
  Google Scholar
• 5. Ausprunk D.H., Folkman J.: Migration and proliferation of endothelialcells in preformed and newly formed blood vessels duringtumor angiogenesis. Microvasc. Res., 1977; 14: 53-65
  Google Scholar
• 6. Baeten C.I., Hillen F., Pauwels P., de Bruine A.P., Baeten C.G.: Prognosticrole of vasculogenic mimicry in colorectal cancer. Dis. Colon.Rectum, 2009; 52: 2028-2035
  Google Scholar
• 7. Bagheri A., Chianeh Y., Rao P.: Role of angiogenic factors in recurrentpregnancy loss. Int. J. Reproduction, Contraception, ObstetricsGynecology, 2013; 2: 497
  Google Scholar
• 8. Barańska P., Jerczyńska H., Pawłowska Z.: Czynnik wzrostu śródbłonkanaczyń – budowa i funkcje. Postępy Biochem., 2005; 51: 12-21
  Google Scholar
• 9. Bianco R., Garofalo S., Rosa R., Damiano V., Gelardi T., Daniele G.,Marciano R., Ciardiello F., Tortora G.: Inhibition of mTOR pathwayby everolimus cooperates with EGFR inhibitors in human tumourssensitive and resistant to anti-EGFR drugs. Br. J. Cancer., 2008; 98:923-930
  Google Scholar
• 10. Biedka M., Makarewicz R., Kopczyńska E., Marszałek A., GoralewskaA., Kardymowicz H.: Angiogenesis and lymphangiogenesisas prognostic factors after therapy in patients with cervical cancer.Contemp. Oncol., 2012; 16: 6-11
  Google Scholar
• 11. Bielecka Z.F., Czarnecka A.M., Solarek W., Kornakiewicz A., SzczylikC.: Mechanisms of acquired resistance to tyrosine kinase inhibitorsin clear – cell renal cell carcinoma (ccRCC). Curr. SignalTransduct. Ther., 2014; 8: 218-228
  Google Scholar
• 12. Cai Y., Xia Q., Su Q., Luo R., Sun Y., Shi Y., Jiang W.: mTOR inhibitorRAD001 (everolimus) induces apoptotic, not autophagic celldeath, in human nasopharyngeal carcinoma cells. Int. J. Mol. Med.,2013; 31: 904-912
  Google Scholar
• 13. Cao Y.: Angiogenesis as a therapeutic target for obesity andmetabolic diseases. Chem. Immunol. Allergy, 2014; 99: 170-179
  Google Scholar
• 14. Cargnello M., Tcherkezian J., Roux P.P.: The expanding role ofmTOR in cancer cell growth and proliferation. Mutagenesis, 2015;30: 169-176
  Google Scholar
• 15. Chouaib S., Messai Y., Couve S., Escudier B., Hasmim M., NomanM.Z.: Hypoxia promotes tumor growth in linking angiogenesis toimmune escape. Front. Immunol., 2012; 3: 21
  Google Scholar
• 16. Chua R.A., Arbiser J.L.: The role of angiogenesis in the pathogenesisof psoriasis. Autoimmunity, 2009; 42: 574-579
  Google Scholar
• 17. Chung H.J., Mahalingam M.: Angiogenesis, vasculogenic mimicryand vascular invasion in cutaneous malignant melanoma – implicationsfor therapeutic strategies and targeted therapies. Expert. Rev.Anticancer Ther., 2014; 14: 621-639
  Google Scholar
• 18. Cibeira M.T., Rozman M., Segarra M., Lozano E., Rosinol L., CidM.C., Filella X., Bladé J.: Bone marrow angiogenesis and angiogenicfactors in multiple myeloma treated with novel agents. Cytokine,2008; 41: 244-253
  Google Scholar
• 19. Cybulski C., Krzystolik K., Murgia A., Górski B., Debniak T.,Jakubowska A., Martella M., Kurzawski G., Prost M., Kojder I., LimonJ., Nowacki P., Sagan L., Białas B., Kaluza J. i wsp.: Germline mutationsin the von Hippel-Lindau (VHL) gene in patients from Poland:disease presentation in patients with deletions of the entire VHLgene. J. Med. Genet., 2002; 39: E38
  Google Scholar
• 20. Czarnecka A.M., Kornakiewicz A., Lian F., Szczylik C.: Futureperspectives for mTOR inhibitors in renal cell cancer treatment.Future Oncol., 2015; 11: 801-817
  Google Scholar
• 21. Czarnecka A.M., Szczylik C., Rini B.: The use of sunitinib in renalcell carcinoma: where are we now? Expert. Rev. Anticancer Ther.,2014; 14: 983-999
  Google Scholar
• 22. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., JainV., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., YancopoulosG.D.: Isolation of angiopoietin-1, a ligand for the TIE2 receptor,by secretion-trap expression cloning. Cell, 1996; 87: 1161-1169
  Google Scholar
• 23. Dmoszyńska A.: Diagnosis and the current trends in multiplemyeloma therapy. Pol. Arch. Med. Wewn., 2008; 118: 563-566
  Google Scholar
• 24. Döme B., Hendrix M.J., Paku S., Tóvári J., Timár J.: Alternativevascularization mechanisms in cancer: pathology and therapeuticimplications. Am. J. Pathol., 2007; 170: 1-15
  Google Scholar
• 25. Downs L.S. Jr., Rogers L.M., Yokoyama Y., Ramakrishnan S.: Thalidomideand angiostatin inhibit tumor growth in a murine xenograftmodel of human cervical cancer. Gynecol. Oncol., 2005; 98:203-210
  Google Scholar
• 26. Dudek A.Z., Zolnierek J., Dham A., Lindgren B.R., Szczylik C.:Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.Cancer, 2009; 115: 61-67
  Google Scholar
• 27. Dusseau J.W., Hutchins P.M.: Hypoxia-induced angiogenesisin chick chorioallantoic membranes: a role for adenosine. Respir.Physiol., 1988; 71: 33-44
  Google Scholar
• 28. Facciabene A., Peng X., Hagemann I.S., Balint K., Barchetti A.,Wang L.P., Gimotty P.A., Gilks C.B., Lal P., Zhang L., Coukos G.: Tumourhypoxia promotes tolerance and angiogenesis via CCL28 and T(reg)cells. Nature, 2011; 475: 226-230
  Google Scholar
• 29. Fajardo L.F., Kwan H.H., Kowalski J., Prionas S.D., Allison A.C.:Dual role of tumor necrosis factor-alpha in angiogenesis. Am. J.Pathol., 1992; 140: 539-544
  Google Scholar
• 30. Ferrara N.: Vascular endothelial growth factor and age-relatedmacular degeneration: from basic science to therapy. Nat. Med.,2010; 16: 1107-1111
  Google Scholar
• 31. Fiedler U., Krissl T., Koidl S., Weiss C., Koblizek T., Deutsch U.,Martiny-Baron G., Marmé D., Augustin H.G.: Angiopoietin-1 and angiopoietin-2share the same binding domains in the Tie-2 receptorinvolving the first Ig-like loop and the epidermal growth factor-likerepeats. J. Biol. Chem., 2003; 278: 1721-1727
  Google Scholar
• 32. Folberg R., Hendrix M.J., Maniotis A.J.: Vasculogenic mimicryand tumor angiogenesis. Am. J. Pathol., 2000; 156: 361-381
  Google Scholar
• 33. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., KoosR.D., Semenza G.L.: Activation of vascular endothelial growth factorgene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol.,1996; 16: 4604-4613
  Google Scholar
• 34. Gerhardt H.: VEGF and endothelial guidance in angiogenic sprouting.Organogenesis, 2008; 4: 241-246
  Google Scholar
• 35. Gerhardt H., Golding M., Fruttiger M., Ruhrberg C., Lundkvist A.,Abramsson A., Jeltsch M., Mitchell C., Alitalo K., Shima D., BetsholtzC.: VEGF guides angiogenic sprouting utilizing endothelial tip cellfilopodia. J. Cell. Biol., 2003; 161: 1163-1177
  Google Scholar
• 36. Ghaneh P., Costello E., Neoptolemos J.P.: Biology and managementof pancreatic cancer. Gut, 2007; 56: 1134-1152
  Google Scholar
• 37. Goudar R.K., Vlahovic G.: Hypoxia, angiogenesis, and lung cancer.Curr. Oncol. Rep., 2008; 10: 277-282
  Google Scholar
• 38. Gryczynski M., Kobos J., Murlewska A., Pietruszewska W.: Prze-żywalność chorych na raka krtani a wybrane czynniki rokownicze.Otolaryngol. Pol., 2003; 57: 329-340
  Google Scholar
• 39. Gryczynski M., Kobos J., Niewiadomska H., Pietruszewska W.:Assessment of cell proliferation antigen Ki-67, protein p53 relatedto apoptosis and angiogenesis in laryngeal cancer. Otolaryngol. Pol.,2000; 54, Suppl. 31: 191-195
  Google Scholar
• 40. Gryczynski M., Papierz W., Niewiadomska H., Kobos J., PietruszewskaW.: Ocena ekspresji czasteczki adhezyjnej CD44, produktugenu nm23 i intensywności angiogenezy u chorych z rakiem krtani.Otolaryngol. Pol., 2000; 54: 669-674
  Google Scholar
• 41. Guglielmelli P., Barosi G., Rambaldi A., Marchioli R., MasciulliA., Tozzi L., Biamonte F., Bartalucci N., Gattoni E., Lupo M.L., FinazziG., Pancrazzi A., Antonioli E., Susini M.C., Pieri L. i wsp.: Safety andefficacy of everolimus, a mTOR inhibitor, as single agent in a phase1/2 study in patients with myelofibrosis. Blood, 2011; 118: 2069-2076
  Google Scholar
• 42. Hefler L.A., Zeillinger R., Grimm C., Sood A.K., Cheng W.F., GadducciA., Tempfer C.B., Reinthaller A.: Preoperative serum vascularendothelial growth factor as a prognostic parameter in ovarian cancer.Gynecol. Oncol., 2006; 103: 512-517
  Google Scholar
• 43. Hirota K., Semenza G.L.: Regulation of angiogenesis by hypoxiainduciblefactor 1. Crit. Rev. Oncol. Hematol., 2006; 59: 15-26
  Google Scholar
• 44. Hlatky L., Tsionou C., Hahnfeldt P., Coleman C.N.: Mammaryfibroblasts may influence breast tumor angiogenesis via hypoxiainducedvascular endothelial growth factor up-regulation and proteinexpression. Cancer Res., 1994; 54: 6083-6086
  Google Scholar
• 45. Hrab M., Olek-Hrab K., Antczak A., Kwias Z., Milecki T.: Interleukin-6(IL-6) and C-reactive protein (CRP) concentration prior to totalnephrectomy are prognostic factors in localized renal cell carcinoma(RCC). Rep. Pract. Oncol. Radiother., 2013; 18: 304-309
  Google Scholar
• 46. Hua H., Li M., Luo T., Yin Y., Jiang Y.: Matrix metalloproteinasesin tumorigenesis: an evolving paradigm. Cell. Mol. Life. Sci., 2011;68: 3853-3868
  Google Scholar
• 47. Ioachim E., Damala K., Tsanou E., Briasoulis E., Papadiotis E., MitselouA., Charhanti A., Doukas M., Lampri L., Arvanitis D.L.: Thrombospondin-1expression in breast cancer: prognostic significance andassociation with p53 alterations, tumour angiogenesis and extracellularmatrix components. Histol. Histopathol., 2012; 27: 209-216
  Google Scholar
• 48. Iruela-Arispe M.L., Lombardo M., Krutzsch H.C., Lawler J., RobertsD.D.: Inhibition of angiogenesis by thrombospondin-1 is mediatedby 2 independent regions within the type 1 repeats. Circulation,1999; 100: 1423-1431
  Google Scholar
• 49. Jimenez Cuenca B.: Mechanism of inhibition of tumoral angiogenesisby thrombospondin-1. Nefrologia, 2003; 23, Suppl. 3: 49-53
  Google Scholar
• 50. Kandemir N.O., Narli Z.I., Kalayci M., Ozdamar S.O.: A rare patternof angiogenesis in meningiomas: glomeruloid microvascularproliferation. Turk. Neurosurg., 2014; 24: 765-769
  Google Scholar
• 51. Komorowski J., Jerczyńska H., Siejka A., Barańska P., ŁawnickaH., Pawłowska Z., Stepień H.: Effect of thalidomide affecting VEGFsecretion, cell migration, adhesion and capillary tube formationof human endothelial EA.hy 926 cells. Life Sci., 2006; 78: 2558-2563
  Google Scholar
• 52. Kornakiewicz A., Solarek W., Bielecka Z.F., Lian F., Szczylik C.,Czarnecka A.M.: Mammalian target of rapamycin inhibitors resistancemechanisms in clear cell renal cell carcinoma. Curr. SignalTransduct. Ther., 2014; 8: 210-218
  Google Scholar
• 53. Kurz H., Burri P.H., Djonov V.G.: Angiogenesis and vascular remodelingby intussusception: from form to function. News Physiol.Sci., 2003; 18: 65-70
  Google Scholar
• 54. Laplante M., Sabatini D.M.: mTOR signaling in growth controland disease. Cell, 2012; 149: 274-293
  Google Scholar
• 55. Leenders W.P., Küsters B., de Waal R.M.: Vessel co-option: howtumors obtain blood supply in the absence of sprouting angiogenesis.Endothelium, 2002; 9: 83-87
  Google Scholar
• 56. Leenders W.P., Küsters B., Verrijp K., Maass C., Wesseling P.,Heerschap A., Ruiter D., Ryan A., de Waal R.: Antiangiogenic therapyof cerebral melanoma metastases results in sustained tumor progressionvia vessel co-option. Clin. Cancer. Res., 2004; 10: 6222-6230
  Google Scholar
• 57. Lionello M., Lovato A., Staffieri A., Blandamura S., Turato C.,Giacomelli L., Staffieri C., Marioni G.: The EGFR-mTOR pathway andlaryngeal cancer angiogenesis. Eur. Arch. Otorhinolaryngol., 2014;271: 757-764
  Google Scholar
• 58. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G.: Cancer metastasisand angiogenesis: an imbalance of positive and negative regulation.Cell, 1991; 64: 327-336
  Google Scholar
• 59. Lockhart A.C., Rothenberg M.L., Berlin J.D.: Treatment for pancreaticcancer: current therapy and continued progress. Gastroenterology,2005; 128: 1642-1654
  Google Scholar
• 60. Mariscalco G., Lorusso R., Sessa F., Bruno V.D., Piffaretti G., BanachM., Cattaneo P., Cozzi G.P., Sala A.: Imbalance between pro-angiogenicand anti-angiogenic factors in rheumatic and mixomatousmitral valves. Int. J. Cardiol., 2011; 152: 337-344
  Google Scholar
• 61. Morisada T., Kubota Y., Urano T., Suda T., Oike Y.: Angiopoietinsand angiopoietin-like proteins in angiogenesis. Endothelium,2006; 13: 71-79
  Google Scholar
• 62. Mysliwiec P., Dadan J.: Znaczenie angiogenezy w raku trzustki.Przegl. Lek., 2009; 66: 155-158
  Google Scholar
• 63. Naumnik W., Chyczewska E., Ossolinska M.: Serum levels ofangiopoietin-1, angiopoietin-2, and their receptor tie-2 in patientswith nonsmall cell lung cancer during chemotherapy. Cancer Invest.,2009; 27: 741-746
  Google Scholar
• 64. Niedźwiecki S., Stepień T., Kopeć K., Kuzdak K., Komorowski J.,Krupiński R., Stepień H.: Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheralblood of patients with thyroid cancers. Cytokine, 2006; 36: 291-295
  Google Scholar
• 65. Otrock Z.K., Mahfouz R.A., Makarem J.A., Shamseddine A.I.: Understandingthe biology of angiogenesis: review of the most importantmolecular mechanisms. Blood Cells Mol. Dis., 2007; 39: 212-220
  Google Scholar
• 66. Paku S., Paweletz N.: First steps of tumor-related angiogenesis.Lab. Invest., 1991; 65: 334-346
  Google Scholar
• 67. Park Y.W., Kang Y.M., Butterfield J., Detmar M., Goronzy J.J., WeyandC.M.: Thrombospondin 2 functions as an endogenous regulatorof angiogenesis and inflammation in rheumatoid arthritis. Am. J.Pathol., 2004; 165: 2087-2098
  Google Scholar
• 68. Pietruszewska W., Niewiadomska H., Kobos J., JózefowiczKorczyńskaM., Gryczyński M.: Significance of angiogenesis in laryngealcancer. Otolaryngol. Pol., 2000; 54, Suppl. 31: 167-170
  Google Scholar
• 69. Plank M.J., Sleeman B.D., Jones P.F.: The role of the angiopoietinsin tumour angiogenesis. Growth Factors, 2004; 22: 1-11
  Google Scholar
• 70. Ramanujan S., Koenig G.C., Padera T.P., Stoll B.R., Jain R.K.: Localimbalance of proangiogenic and antiangiogenic factors: a potentialmechanism of focal necrosis and dormancy in tumors. Cancer Res.,2000; 60: 1442-1448
  Google Scholar
• 71. Ravaud A, Gross-Goupil M.: Overcoming resistance to tyrosinekinase inhibitors in renal cell carcinoma. Cancer Treat. Rev., 2012;38: 996-1003
  Google Scholar
• 72. Reginato S., Gianni-Barrera R., Banfi A.: Taming of the wild vessel:promoting vessel stabilization for safe therapeutic angiogenesis.Biochem. Soc. Trans., 2011; 39: 1654-1658
  Google Scholar
• 73. Reisinger K., Baal N., McKinnon T., Münstedt K., Zygmunt M.:The gonadotropins: tissue-specific angiogenic factors? Mol. Cell.Endocrinol., 2007; 269: 65-80
  Google Scholar
• 74. Reiss Y., Machein M.R., Plate K.H.: The role of angiopoietins during angiogenesis in gliomas. Brain Pathol., 2005; 15: 311-317
  Google Scholar
• 75. Sacewicz I., Wiktorska M., Wysocki T., Niewiarowska J.: Mechanizmyangiogenezy nowotworowej. Postępy Hig. Med. Dośw.,2009; 63: 159-168
  Google Scholar
• 76. Sadłecki P., Walentowicz-Sadłecka M., Szymański W., Grabiec M.:Porównanie stężeń VEGF, IL-8 oraz β-FGF w surowicy krwi i płynieotrzewnowym u pacjentek leczonych z powodu raka jajnika. Ginekol.Pol., 2011; 82: 498-502
  Google Scholar
• 77. Semenza G.L.: Targeting HIF-1 for cancer therapy. Nat. Rev.Cancer, 2003; 3: 721-732
  Google Scholar
• 78. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F.,Breitman M.L., Schuh A.C.: Failure of blood-island formation andvasculogenesis in Flk-1-deficient mice. Nature, 1995; 376: 62-66
  Google Scholar
• 79. Skotnicki A.B., Wolska-Smoleń T., Jurczyszyn A.: Multiple myeloma- new therapeutic perspectives. Przegl. Lek., 1999; 56, Suppl.1: 67-72
  Google Scholar
• 80. Soker S.: Neuropilin in the midst of cell migration and retraction.Int. J. Biochem. Cell Biol., 2001; 33: 433-437
  Google Scholar
• 81. Sundberg C., Nagy J.A., Brown L.F., Feng D., Eckelhoefer I.A.,Manseau E.J., Dvorak A.M., Dvorak H.F.: Glomeruloid microvascularproliferation follows adenoviral vascular permeability factor/vascularendothelial growth factor-164 gene delivery. Am. J. Pathol.,2001; 158: 1145-1160
  Google Scholar
• 82. Swidzińska E., Naumnik W., Chyczewska E.: Angiogeneza i neoangiogeneza– znaczenie w raku płuca i innych nowotworach. Pneumonol.Alergol. Pol., 2006; 74: 414-420
  Google Scholar
• 83. Tahergorabi Z., Khazaei M.: The relationship between inflammatorymarkers, angiogenesis, and obesity. ARYA Atheroscler., 2013;9: 247-253
  Google Scholar
• 84. Tanaka F., Oyanagi H., Takenaka K., Ishikawa S., Yanagihara K.,Miyahara R., Kawano Y., Li M., Otake Y., Wada H.: Glomeruloid microvascular proliferation is superior to intratumoral microvesseldensity as a prognostic marker in non-small cell lung cancer. CancerRes., 2003; 63: 6791-6794
  Google Scholar
• 85. Voros G., Maquoi E., Demeulemeester D., Clerx N., Collen D.,Lijnen H.R.: Modulation of angiogenesis during adipose tissue developmentin murine models of obesity. Endocrinology, 2005; 146:4545-4554
  Google Scholar
• 86. Walski M., Frontczak-Baniewicz M.: Cechy ultrastrukturalneprawidłowego i dysfunkcyjnego śródbłonka naczyń krwionośnych.Pol. Arch. Med. Wewn., 2007; 117, Suppl.: 46-49
  Google Scholar
• 87. Wysocki P.J., Zolnierek J., Szczylik C., Mackiewicz A.: Targetedtherapy of renal cell cancer. Curr. Opin. Investig. Drugs, 2008; 9:570-575
  Google Scholar
• 88. Xiong H.Q., Rosenberg A., LoBuglio A., Schmidt W., Wolff R.A.,Deutsch J., Needle M., Abbruzzese J.L.: Cetuximab, a monoclonal antibodytargeting the epidermal growth factor receptor, in combinationwith gemcitabine for advanced pancreatic cancer: a multicenterphase II trial. J. Clin. Oncol., 2004; 22: 2610-2616
  Google Scholar
• 89. Yamanaka H.: Rheumatoid arthritis and angiogenesis. Intern.Med., 2003; 42: 297-299
  Google Scholar
• 90. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J.,Holash J.: Vascular-specific growth factors and blood vessel formation.Nature, 2000; 407: 242-248
  Google Scholar
• 91. Yu Q.: The dynamic roles of angiopoietins in tumor angiogenesis.Future Oncol., 2005; 1: 475-484
  Google Scholar
• 92. Żołnierek J., Nurzyński P., Langiewicz P., Oborska S., WaśkoGrabowskaA., Kuszatal E., Obrocka B., Szczylik C.: Efficacy of targetedtherapy in patients with renal cell carcinoma with pre-existing ornew bone metastases. J. Cancer Res. Clin. Oncol., 2010; 136: 371-378
  Google Scholar

Full text